Continuous Glucose Monitoring Data

Seagrove estimates that there are over 3.1 M CGM users domestically with the majority using the Abbott FreeStyle Libre. Growth in the space has stemmed from fingerstick replacement claims, Medicare coverage and CGM integration with AID systems.

Seagrove estimates that there are over 7.5 M CGM users around the globe with growth coming from expansion into Europe and Asia as well as price reductions allowing self-pay for sensors in areas without insurance coverage.

Glucose monitoring has progressed from early blood-based test strips in the 1960s to more accurate and convenient BGM systems in the 1990s to today’s continuous glucose monitors. Pumps have gone from stand-alone pager sized devices to today’s automated insulin delivery systems.

Medtronic commercialized the industry’s first CGM and paved the way with conducting outcomes studies that would eventually lead to insurance coverage. The current Guardian Sensor 3 is in use in most countries with Guardian Sensor 4 in limited launch mode (EU) and awaiting FDA approval.

Dexcom started out developing an implantable sensor and then migrated to the platform that led to the industry’s first seven-day sensor. The G4 Platinum brought industry-leading accuracy and today’s G6 sensor drives most AID systems. The G7 is currently under review by the FDA.

Abbott completely revolutionized industrial design for sensors leading to the flat, user-friendly Libre and then followed with the first 14-day sensor that has taken the lead for worldwide market share. Abbott also agressively priced Libre out-of-the-gate allowing for broad coverage and self-pay models.

Future product differentiation will likely focus on cheaper manufacturing processes, multi-analyte readouts, and predictive analytics that can further improve time-in-range.

Cost and not wanting to wear a medical devvice on the body top the list for people not wanting to use a CGM. Outside of intensively managed groups, physician indifference has also reduced utilization.